Repligen (RGEN) is trading up at $185.24 (+1.95%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
Analyst price targets on RGEN
One firm's current price target on Repligen: $225 — 21% above the current $185. Each is tracked to its date and scored the same way a member's call is.
- UBS $195 → $225 by Sep 2027 Sep 29, 2026 via Investing.com · UBS's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Repligen revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $104.5M | $141.2M | $194.0M | $270.2M | $366.3M | $670.5M | $801.5M | $632.4M | $634.4M | $738.3M |
| Growth (year over year) | +25.1% | +35.1% | +37.4% | +39.3% | +35.5% | +83.1% | +19.5% | −21.1% | +0.3% | +16.4% |
| Gross profit | $57.4M | $74.2M | $107.5M | $151.1M | $209.6M | $391.3M | $455.7M | $278.4M | $274.6M | $386.2M |
| Gross margin | 54.9% | 52.5% | 55.4% | 55.9% | 57.2% | 58.3% | 56.9% | 44.0% | 43.3% | 52.3% |
| Operating income | $16.0M | $14.0M | $26.0M | $36.1M | $69.8M | $167.2M | $224.7M | $47.7M | −$35.1M | $55.2M |
| Operating margin | 15.3% | 9.9% | 13.4% | 13.4% | 19.1% | 24.9% | 28.0% | 7.5% | −5.5% | 7.5% |
| Net income | $11.7M | $28.4M | $16.6M | $21.4M | $59.9M | $128.3M | $186.0M | $35.6M | −$25.5M | $48.9M |
| Net margin | 11.2% | 20.1% | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 5.6% | −4.0% | 6.6% |
| EPS (diluted) | $0.34 | $0.72 | $0.37 | $0.44 | $1.11 | $2.24 | $3.24 | $0.63 | −$0.46 | $0.86 |
| Balance sheet | ||||||||||
| Cash and equivalents | $122.2M | $173.8M | $193.8M | $528.4M | $717.3M | $603.8M | $523.5M | $751.3M | $757.4M | $566.0M |
| Total assets | $288.9M | $743.5M | $774.6M | $1.40B | $1.90B | $2.36B | $2.53B | $2.83B | $2.83B | $2.95B |
| Total liabilities | $120.1M | $152.0M | $159.1M | $340.3M | $373.7M | $608.3M | $620.9M | $866.3M | $856.9M | $843.6M |
| Long-term debt | — | — | — | — | — | — | — | — | $525.6M | $542.2M |
| Shareholders' equity | $168.8M | $591.5M | $615.6M | $1.06B | $1.53B | $1.75B | $1.91B | $1.96B | $1.97B | $2.11B |
| Cash flow | ||||||||||
| Operating cash flow | $7.52M | $17.5M | $32.8M | $67.2M | $62.6M | $119.0M | $172.1M | $113.9M | $175.4M | $117.4M |
| Capital expenditure | $4.33M | $5.45M | $10.6M | $18.5M | $22.5M | $67.1M | $84.8M | $36.2M | $25.7M | $23.5M |
| Free cash flow | $3.20M | $12.0M | $22.1M | $48.7M | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
| Share buybacks | — | — | — | — | — | $0 | $0 | $14.4M | $0 | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $154.9M | $167.5M | $169.2M | $182.4M | $188.8M | $197.9M | $194.3M | $204.1M |
| Growth (year over year) | +9.7% | +0.6% | +10.4% | +14.8% | +21.9% | +18.1% | +14.8% | +11.9% |
| Gross profit | $77.5M | $38.8M | $91.4M | $93.0M | $100.5M | $101.4M | $108.3M | $110.0M |
| Gross margin | 50.0% | 23.2% | 54.0% | 51.0% | 53.2% | 51.2% | 55.7% | 53.9% |
| Operating income | −$7.83M | −$36.5M | $6.58M | $13.9M | $16.8M | $17.9M | $15.9M | $14.0M |
| Operating margin | −5.1% | −21.8% | 3.9% | 7.6% | 8.9% | 9.0% | 8.2% | 6.8% |
| Net income | −$654.0K | −$33.9M | $5.83M | $14.9M | $14.9M | $13.3M | $8.33M | $5.01M |
| Net margin | −0.4% | −20.2% | 3.4% | 8.2% | 7.9% | 6.7% | 4.3% | 2.5% |
| EPS (diluted) | −$0.01 | −$0.61 | $0.10 | $0.26 | $0.26 | $0.24 | $0.15 | $0.09 |
| Balance sheet | ||||||||
| Cash and equivalents | $784.0M | $757.4M | $697.2M | $708.9M | $748.7M | $566.0M | $582.6M | $606.8M |
| Total assets | $2.83B | $2.83B | $2.85B | $2.90B | $2.92B | $2.95B | $2.93B | $2.95B |
| Total liabilities | $814.0M | $856.9M | $866.7M | $839.9M | $840.6M | $843.6M | $825.3M | $838.1M |
| Long-term debt | — | $525.6M | — | — | $537.9M | $542.2M | $546.6M | $551.0M |
| Shareholders' equity | $2.02B | $1.97B | $1.99B | $2.06B | $2.08B | $2.11B | $2.11B | $2.11B |
| Cash flow | ||||||||
| Operating cash flow | $49.3M | $39.2M | $15.0M | $28.6M | $48.1M | $25.7M | $28.3M | $32.8M |
| Capital expenditure | $6.98M | $5.54M | $3.56M | $7.10M | $4.70M | $8.15M | $4.71M | $5.33M |
| Free cash flow | $42.3M | $33.6M | $11.4M | $21.5M | $43.4M | $17.6M | $23.6M | $27.4M |
From Repligen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Repligen
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
- Headquarters
- Waltham, Massachusetts From SEC filings, Oct 2026
Recent News (5)
-
Repligen stock price target reaffirmed at $225 by UBS on growth outlook
Repligen stock price target reaffirmed at $225 by UBS on growth outlook
-
Repligen CEO Olivier Loeillot sells $976,680 in company stock
Repligen CEO Olivier Loeillot sells $976,680 in company stock
-
Repligen CEO Loeillot sells $2.46m in shares
Repligen CEO Loeillot sells $2.46m in shares
-
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate…
-
Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more (STRIP:Private) Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more (STRIP:Private) Seeking Alpha
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International